Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.32 |
| ▸ | PRMT1 | Q99873 | 2/20 | 0.32 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.31 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.31 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4119688 | 0.93 | SMYD2 (0.34) | SMYD2CYP3A4HTTSMN1; SMN2ABL1 | |
| SCHEMBL4130620 | 0.87 | SMYD2 (0.33) | SMYD2CYP3A4HTTSMN1; SMN2ABL1 | |
| SCHEMBL29583645 | 0.86 | SMYD2 (0.36) | SMYD2CYP3A4HTTSMN1; SMN2ABL1 | |
| SCHEMBL31163018 | 0.85 | SMYD2 (0.35) | SMYD2CYP3A4HTTSMN1; SMN2ABL1 | |
| SCHEMBL4121310 | 0.85 | SMYD2 (0.35) | SMYD2CYP3A4HTTSMN1; SMN2ABL1 | |
| SCHEMBL20446429 | 0.85 | SMYD2 (0.35) | SMYD2CYP3A4HTTSMN1; SMN2ABL1 | |
| SCHEMBL2912786 | 0.85 | SMYD2 (0.38) | SMYD2CYP3A4HTTSMN1; SMN2ABL1 | |
| SCHEMBL2912500 | 0.84 | OPRL1 (0.38) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL17080491 | 0.83 | CYP3A4 (0.40) | SMYD2CYP3A4HTTSMN1; SMN2ABL1 | |
| SCHEMBL29235827 | 0.82 | SMYD2 (0.34) | SMYD2CYP3A4HTTSMN1; SMN2ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318690-A1 | Benzisoxazole Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
| US-20090318690-A1 | Benzisoxazole Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
| EP-2017275-A1 | BENZISOXAZOLE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2009-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318690-A1 | Benzisoxazole Compound | NR1I2, NR1I3, NR0B1 | SMYD2 3091/4885CYP3A4 157/4885HTT 3905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.